Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
Issued Date
2022-12-01
Resource Type
eISSN
17560500
Scopus ID
2-s2.0-85139154661
Pubmed ID
36184602
Journal Title
BMC Research Notes
Volume
15
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC Research Notes Vol.15 No.1 (2022)
Suggested Citation
Tarning J., von Seidlein L., Dondorp A.M., White N.J., Maude R.J. Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria. BMC Research Notes Vol.15 No.1 (2022). doi:10.1186/s13104-022-06212-y Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83525
Title
Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria
Other Contributor(s)
Abstract
Objective: Antimalarial chemoprophylaxis for high risk groups in endemic areas of Southeast Asia has the potential to reduce malaria transmission and accelerate elimination. However, the optimal choice of medication and dosing for many potential candidates is not clear. For a planned randomised controlled trial of prophylaxis for forest goers in Cambodia, artemether-lumefantrine (AL) was selected because of its ongoing efficacy and excellent tolerability and safety. As AL had not been used before for this purpose, a previously published pooled pharmacometric meta-model was used to determine the optimal dosing schedule. Results: A full 3 day AL treatment course given twice a month, and twice daily treatment given once a week, resulted in trough concentrations consistently above the therapeutic threshold of 200 ng/mL. However, the most favourable exposure profile, and arguably most practical dosing scenario, was an initial 3 day full AL treatment course followed by twice daily dosing given once a week for the duration of chemoprevention. The latter was adopted as the dosing schedule for the trial.